Lysosomes and trivalent arsenic treatment in acute promyelocytic leukemia

Journal of the National Cancer Institute

Volumn 99, Issue 1, 2007, Pages 41-52

  Kitareewan, Sutisak ^a   Roebuck, B D ^a   Demidenko, Eugene ^a,b   Sloboda, Roger D ^c   Dmitrovsky, Ethan ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^c Dartmouth College   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENITE SODIUM; CATHEPSIN L; DYE; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEINASE INHIBITOR; RETINOIC ACID RECEPTOR ALPHA; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; ARSENOUS ACID DERIVATIVE; CASPASE 3; CASPASE 7; CATHEPSIN; CYSTEINE PROTEINASE; ONCOPROTEIN; PEPTIDE HYDROLASE; PROMYELOCYTIC LEUKEMIA RETINOIC ACID RECEPTOR ALPHA FUSION ONCOPROTEIN; PROMYELOCYTIC LEUKEMIA-RETINOIC ACID RECEPTOR ALPHA FUSION ONCOPROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL FRACTIONATION; CELL LYSATE; COMPARATIVE STUDY; CONTROL GROUP; CONTROLLED STUDY; CYTOSOL; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOGOLD LABELING; IN VITRO STUDY; LYSOSOME; NONHUMAN; NONLINEAR REGRESSION ANALYSIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN DEGRADATION; RANK SUM TEST; TRANSMISSION ELECTRON MICROSCOPY; CELL CULTURE; DOSE RESPONSE; DRUG EFFECT; METABOLISM; METHODOLOGY; TIME;

ANTINEOPLASTIC AGENTS; ARSENITES; CASPASE 3; CASPASE 7; CATHEPSINS; CYSTEINE ENDOPEPTIDASES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; LYSOSOMES; MICROSCOPY, ELECTRON, TRANSMISSION; ONCOGENE PROTEINS, FUSION; PEPTIDE HYDROLASES; RESEARCH DESIGN; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 33846948645     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djk004     Document Type: Article

References (64)

1. Melnick A, Licht JD. Deconstxucting a disease: RARα, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 1999;93:3167-215.
2. Zhu J, Gianni M, Kop E, Honore N, Chelbi-Alix M, Koken M, et al. Retinoic acid induces proteasome-dependent degradation of retionic acid receptor α (RARα) and oncogenic RARα fusion protein. Proc Nad Acad SciUS A 1999;96:14807-12.
3. Kitareewan S, Pitha-Rowe I, Sekula D, Lowrey CH, Nemeth MJ, Golub TR, et al. UBE1L is a retinoid target that triggers PML/RARα degradation and apoptosis in acute promyelocytic leukemia. Proc Nad Acad Sci U S A 2002;99:3806-11.
4. Nervi C, Ferrara FF, Fanelli M, Rippo MR, Tomassini B, Ferrucci PF, et al. Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARa fusion protein. Blood 1998;92:2244-51.
5. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RARUα/PML proteins. Blood 1996;88:1052-61.
6. Miller WH Jr, Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res 2002;62:3893-903.
7. Zhang P, Wang S, Hu L, Shi F, Qiu F, Hong L, et al. Treatment of acute promyelocytic leukemia with intravenous arsenic trioxide. Chin J Hematol 1996;17:58-60.
8. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997;89:3354-60.
9. Vega L, Styblo M, Patterson R, Cullen W, Wang C, Germolec D. Differential effects of trivalent and pentavalent arsenicals on cell proliferation and cytokine secretion in normal human epidermal keratinocytes. Toxicol Appl Pharmacol 2001;172:225-32.
10. Thomas DJ, Styblo M, Lin S. The cellular metabolism and systemic toxicity of arsenic. Toxicol Appl Pharmacol 2001;176:127-44.
11. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998;339:1341-8.
12. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001;19:3852-60.
13. 3 exerts dose-dependent dual effects on APL cells. Blood 1997; 89:3345-53.
14. Lallemand-Breitenbach V, Guillemin MC, Janin A, Daniel MT, Degos L, Kogan SC, et al. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med 1999;189:1043-52.
15. 3)-induced apoptosis and differentiation in retinoic acid-resistant acute promyelocytic leukemia model in hGM-CSF-produc- ing transgenic SCID mice. Leukemia 2000;14:431-8.
16. Gianni M, Koken MHM, Chelbi-Alix MK, Benoit G, Lanotte M, Chen Z, et al. Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells. Blood 1998;91:4300-10.
17. 3- induced PML or PML/retinoic acid receptor a degradation. J Exp Med 2001;193:1361-71.
18. Chen YC, Lin-Shiau SY, Lin JK Involvement of reactive oxygen species and caspase 3 activation in arsenic-induced apoptosis. J Cell Physiol 1998;177:324-33.
19. Kitamura K, Minami Y, Yamamoto K, Akao Y, Kiyoi H, Saito H, et al. Involvement of CD95-independent caspase 8 activation in arsenic trioxide- induced apoptosis. Leukemia 2000;14:1743-50.
20. Nason-Burchenal K, Allopenna J, Begue A, Stehelin D, Dmitrovsky E, Martin P. Targeting of PML/RARa is lethal to retinoic acid-resistant promyelocytic leukemia cells. Blood 1998;92:1758-67.
21. Akao Y, Nakagawa Y, Akiyama K. Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro. FEBS Lett 1999;455:59-62.
22. Seol JG, Park WH, Kim ES, Jung CW, Hyun JM, Lee YY, et al. Potential role of caspase-3 and -9 in arsenic trioxide-mediated apoptosis in PCI-1 head and neck cancer cells. Int J Oncol 2001;18:249-55.
23. Bajenova O, Tang B, Pearse R, Feinman R, Childs BH, Michaeli J. RIP kinase is involved in arsenic-induced apoptosis in multiple myeloma cells. Apoptosis 2004;9:561-71.
24. Kong B, Huang S, Wang W, Ma D, Qu X, Jiang J, et al. Arsenic trioxide induces apoptosis in cisplatin-sensitive and -resistant ovarian cancer cell lines. Int J Gynecol Cancer 2005;15:872-7.
25. Mullins C, Bonifacino JS. The molecular machinery for lysosome biogenesis. Bioessays 2001;23:333-13.
26. Jaattela M, Tschopp J. Caspase-independent cell death in T lymphocytes. Nat Immunol 2003;4:416-23.
27. Brunk UT, Neuzil J, Eaton JW. Lysosomal involvement in apoptosis. Redox Rep 2001;6:91-7.
28. Turk B, Stoka V, Rozman-Pungercar J, Cirman T, Droga-Mazovec G, Oresic K, et al. Apoptotic pathways: involvement of lysosomal proteases. Biol Chem 2002;383:1035-14.
29. Yuan XM, Li W, Dalen H, Lotem J, Kama R, Sachs L, et al. Lysosomal destabilization in p53-induced apoptosis. Proc Nad Acad Sci USA 2002;99:6286-91.
30. Foghsgaard L, Wissing D, Mauch D, Lademann U, Bastholm L, Boes M, et al. Cathepsin B acts as a dominant execution protease in tumor cell apoptosis induced by tumor necrosis factor. J Cell Biol 2001;153:999-1010.
31. Guicciardi ME, Deussing J, Miyoshi H, Bronk SF, Svingen PA, Peters C, et al. Cathepsin B contributes to TNF-alpha-mediated hepatocyte apoptosis by promoting mitochondrial release of cytochrome c. J Clin Invest 2000;106:1127-37.
32. Dietrich N, Thastrup J, Holmberg C, Gyrd-Hansen M, Fehrenbacher N, Lademann U, et al. JNK2 mediates TNF-induced cell death in mouse embryonic fibroblasts via regulation of both caspase and cathepsin protease pathways. Cell Death Differ 2004;11:301-13.
33. Brunk UT, Svensson I. Oxidative stress, growth factor starvation and Fas activation may all cause apoptosis through lysosomal leak. Redox Rep 1999;4:3-11.
34. Lane AA, Ley TJ. Neutrophil elastase cleaves PML-RARα and is important for development of acute promyelocytic leukemia in mice. Cell 2003;115:305-18.
35. Fehrenbacher N, Gyrd-Hansen M, Poulsen B, Felbor U, Kallunki T, Boes M, et al. Sensitization to the lysosomal cell death pathway upon immortalization and transformation. Cancer Res 2004;64:5301-10.
36. Kawasaki G, Kato Y, Mizuno A. Cathepsin expression in oral squamous cell carcinoma: relationship with clinicopathologic factors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002;93:446-54.
37. Erdal H, Berndtsson M, Castro J, Brunk U, Shoshan MC, Linder S. Induction of lysosomal membrane permeabilization by compounds that activate p53-independent apoptosis. Proc Nad Acad Sci U S A 2005;102:192-7.
38. Fehrenbacher N, Jaattela M. Lysosomes as targets for cancer therapy. Cancer Res 2005;65:2993-5.
39. Nason-Burchenal K, Maerz W, Albanell J, Allopenna J, Martin P, Moore MAS, et al. Common defects of different retinoic acid resistant promyelocytic leukemia cells are persistent telomerase activity and nuclear body disorganization. Differentiation 1997;61:321-31.
40. Lanotte M, Martin-Thouvenin V, Najman S, Balerini P, Valensi F, Berger R. NB4, a maturation inducible cell line with t(l5;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 1991;77:1080-6.
41. Langenfeld J, Kiyokawa H, Sekula D, Boyle J, Dmitrovsky E. Posttranslational regulation of cyclin D1 by retinoic acid: a chemopreven- tion mechanism. Proc Natl Acad Sci U S A 1997;94:12070-1.
42. Wetterhahn KE, Dudek EJ, Shumilla JA, Lannon BM, Elmore LC, Barchowsky A Possible mechanisms for arsenic-induced proliferative diseases. Proceedings of the Seventh Pacific Basin Conference on Hazardous
43. Waste; 1996; Kuala Lumpur (Malaysia); CONF-9611157; 446-66. Pacific Basin Consortium of Hazardous Waste Research.
44. Zhang TD, Chen GQ, Wang ZG, Wang ZY, Chen SJ, Chen Z. Arsenic trioxide, a therapeutic agent for APL. Oncogene 2001;20:7146-53.
45. Douer D, Tallman MS. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. J Clin Oncol 2005;23: 2396-110.
46. Ishitsuka K, Shirahashi A, Iwao Y, Shishime M, Takamatsu Y, Takatsuka Y, et al. Bone marrow necrosis in a patient with acute promyelocytic leukemia during re-induction therapy with arsenic trioxide. Eur J Haematol 2004;72:280-1.
47. Ollinger K, Brunk UT. Cellular injury induced by oxidative stress is mediated through lysosomal damage. Free Radic Biol Med 1995;19:565-74.
48. Boll I. Morphologic phase-contrast cinematographic studies on the behavior of bone marrow cells in vitro. X. Myeloblasts and monoblasts. Blut 1976;32:115-30.
49. Campbell EJ, Silverman EK, Campbell MA. Elastase and cathepsin G of human monocytes. Quantification of cellular content, release in response to stimuli, and heterogeneity in elastase-mediated proteolytic activity. J Immunol 1989;143:2961-8.
50. Sahu GR, Jena RK. Significance of intracellular arsenic trioxide for therapeutic response in acute promyelocytic leukemia. Am J Hematol 2005; 78:113-6.
51. Mullin KA, Foth BJ, Ilgoutz SC, CallaghanJM, Zawadzki JL, McFadden GI, et al. Regulation of an endoplasmic reticulum membrane protein in a tubular lysosome in Leishmania mexicana. Mol Biol Cell 2001;12:2364-77.
52. Fowler BA. General subcellular effects of lead, mercury, cadmium, and arsenic. Environ Health Perspect 1978;22:37-11.
53. Berry JP, Galle P. Selenium-arsenic interaction in renal cells: role of lysosomes. Electron microprobe study. J Submicrosc Cytol Pathol 1994;26: 203-10.
54. Link G, Pinson A, Hershko C. Iron loading of cultured cardiac myocytes modified sarcolemmal structure and increase lysosomal fragility. J Lab Clin Med 1993;121:127-34.
55. Brunk UT, Terman A. The mitochondrial-lysosomal axis theory of aging: accumulation of damaged mitochondria as a result of imperfect autopha- gocytosis. Eur J Biochem 2002;269:1996-2002.
56. Barchowsky A, Dudek EJ, Treadwell MD, Wetterhahn KE. Arsenic induces oxidant stress and NF-κB activation in cultured aorta endothelial cells. Free Radic Biol Med 1996;21:783-90.
57. Jing Y, Dai J, Chalmers-Redman RME, Tatton WG, Waxman S. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 1999;94:2102-11.
58. Sternsdorf T, Puccetti E, Jensen K, Hoelzer D, Will H, Ottmann OG, et al. PIC-l/SUMO-1-modified PML-retinoic acid receptor a mediates arsenic trioxide-induced apopotosis in acute promyelocytic leukemia. Mol Cell Biol 1999;19:5170-8.
59. Cai X, Shen YL, Zhu Q, Jia PM, Yu Y, Zhou L, et al. Arsenic trioxide- induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia 2000; 14: 262-70.
60. Zang Y, Beard RL, Chandraratna RA, Kang JX. Evidence of a lysosomal pathway for apoptosis induced by the synthetic retinoid CD437 in human leukemia HL-60 cells. Cell Death Differ 2001;8:477-85.
61. Kagedal K, Johansson U, Ollinger K. The lysosomal protease cathepsin D mediates apoptosis induced by oxidative stress. FASEB J 2001;15:1592-4.
62. Kagedal K, Johansson AC, Johansson U, Heimlich G, Roberg K, Wang NS, et al. Lysosomal membrane permeabilization during apoptosis- involvement of Bax? Int J Exp Pathol 2005;86:309-21.
63. Guicciardi ME, Bronk SF, Werneburg NW, Yin XM, Gores GJ. Bid is upstream of lysosome-mediated caspase 2 activation in tumor necrosis factor alpha-induced hepatocyte apoptosis. Gastroenterology 2005; 129:269-84.
64. Nason-Burchenal K, Takle G, Pace U, Flynn S, Allopenna J, Martin P, et al. Targeting the PML/RARα translocation product triggers apoptosis in promyelocytic leukemia cells. Oncogene 1998;17:1759-68.